Abstract
A syndrome of eosinophilia with systemic symptoms associated with ingestion of L-tryptophan was first described in late 1989.1 By Aug. 24, 1990, 1536 cases of eosinophilia-myalgia syndrome (EMS) had been reported to the Centers for Disease Control.2 The criteria for diagnosis are an eosinophil count greater than 1000 cells/rnrn,3 generalized myalgias, and absence of infection or neoplasm to account for the clinical symptoms. The cutaneous manifestations include a diffuse, pruritic, morbilliform eruption; urticaria; angioedema; sclerodermatous changes; and hair 10ss.3 We report a patient with EMS who had a severe, persistent, telogen effluvium.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
